US FDA lowers risk classification for cardiac allograft gene expression profiling tests
This article was originally published in SRA
The US Food and Drug Administration has classified cardiac allograft gene expression profiling test systems as medium-risk (Class II) devices1 and established special controls that would provide a reasonable assurance of safety and effectiveness of such products2,3.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.